Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Co-Diagnostics Inc
NASDAQ CODX
Data sourced from
and
and
Co-Diagnostics Inc Liabilities to Equity Ratio 3 year CAGR for the year ending December 31, 2023: 44.41%
Co-Diagnostics Inc Liabilities to Equity Ratio 3 year CAGR is 44.41% for the year ending December 31, 2023, a 226.08% change year over year. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Co-Diagnostics Inc Liabilities to Equity Ratio for the year ending December 31, 2022 was 0.07, a -60.64% change year over year.
-
Co-Diagnostics Inc Liabilities to Equity Ratio for the year ending December 31, 2021 was 0.19, a 179.18% change year over year.
-
Co-Diagnostics Inc Liabilities to Equity Ratio for the year ending December 31, 2020 was 0.07, a -75.26% change year over year.
-
Co-Diagnostics Inc Liabilities to Equity Ratio for the year ending December 31, 2019 was 0.28, a 111.16% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: CODX
| CEO | Mr. Dwight H. Egan |
| IPO Date | July 12, 2017 |
| Location | United States |
| Headquarters | 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109 |
| Employees | 155 |
| Sector | Healthcare |
| Industry | Medical devices |
Description
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Key trends
Similar companies
Clearpoint Neuro Inc
NA
NA
SurModics Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email